Form 4: Krystal Biotech CEO Krish Krishnan Reports Stock Transaction
SEC Form 4 Filing
Krystal Biotech's CEO, Krish Krishnan, reports the surrender of shares for tax withholding upon vesting of restricted stock.
Summary
- On February 26, 2024, Krish Krishnan, the President and CEO of Krystal Biotech, Inc., surrendered 3,791 shares of common stock to the company for tax withholding purposes.
- This action was related to the vesting of 10,200 shares of restricted stock.
- The price per share was $157, based on the closing price of Krystal Biotech's common stock on NASDAQ on that date.
- Following the transaction, Krishnan directly owns 1,630,547 shares.
- Krishnan also indirectly owns 1,574,206 shares through his spouse, Suma M. Krishnan, 90,000 shares through the Krishnan Spousal Trust, and 50,000 shares through the Krishnan Family Trust.
Sentiment
Score: 5
Explanation: This is a neutral event. It's a standard reporting of stock transactions by an executive, with no inherent positive or negative implications for the company's performance.
Industry Context
This is a routine disclosure of insider transactions, required by the SEC to ensure transparency and prevent insider trading. It provides investors with information about the trading activities of company executives and directors.
Key Dates
| Date | Description |
|---|---|
| 02/26/2024 | Date of stock transaction (surrender of shares for tax withholding). |
| 02/26/2024 | Vesting date of 10,200 shares of restricted stock. |
| 02/28/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.